This toolkit is a comprehensive set of practical tools and resources designed to support country-level risk communication and community engagement (RCCE) practitioners, decision-makers and partners to plan and implement readiness and response activities for Ebola disease outbreaks. The toolkit conta...ins: information about Ebola disease; RCCE considerations on how to approach key issues during Ebola disease outbreaks; tools for understanding the context in which Ebola disease outbreaks occur; methods for collecting data to inform strategy development and bring evidence into the planning and implementation of activities; guidance to support prevention and response interventions; and links to existing RCCE tools and training. It is one of a suite of toolkits on RCCE readiness and response to a range of disease and response areas.
more
This toolkit is a comprehensive set of practical tools and resources designed to support country-level risk communication and community engagement (RCCE) practitioners, decision-makers, and partners to plan and implement readiness and response activities for yellow fever outbreaks. The toolkit conta...ins: information about yellow fever; RCCE considerations for how to approach key issues during yellow fever outbreaks; tools for understanding the context in which yellow fever outbreaks occur; methods for collecting data to inform strategy development and bring evidence into planning and implementation of activities; guidance to support vector control and immunization campaigns; and links to existing RCCE tools and training. It is one of a suite of toolkits on RCCE readiness and response to a range of disease and response areas.
more
This operational guidance provides a structured approach to support countries in sustaining priority services for HIV, viral hepatitis and sexually transmitted infections in the context of reduced external funding. The guidance is intended for national governments, public health programmes, communit...y-led organizations, civil society, technical partners and donors working to safeguard priority services, support phased adaptation, protect health outcomes and preserve hard-won gains.
more
Scope: The purpose of this guideline is to assist health care providers caring for patients with suspected or confirmed arboviral disease caused by dengue, chikungunya, Zika or yellow fever viruses. This guideline includes recommendations on the management of patients admitted to health care facilit...ies (defined for the purpose of this guidance as “severe disease”) and those seen in outpatient facilities (defined for the purpose of this guidance as “non-severe disease”).
Target audience: This guideline is designed primarily for health care providers who manage patients with clinically apparent arboviral infections. The guideline can be applied at all levels of the health system, including community-based care, primary care, emergency departments and hospital wards.
more
Integrated Outbreak Analytics (IOA) applies a multidisciplinary approach to understanding outbreak dynamics and to inform outbreak response. It aims to drive comprehensive, accountable, and effective public health and clinical strategies by enabling communities, and national and subnational health a...uthorities to use data for operational decision-making. IOA embraces a holistic perspective of outbreak dynamics throughout: from the trigger questions to the data that are collected or accessed, to the interpretation of results and the recommendations that follow. In addition, IOA promotes co-development and monitoring of evidence informed actions.
The IOA toolkit aims to provide a clear understanding of IOA and highlight the importance of using an integrated, holistic approach to manage outbreak responses. It provides step-by-step guidance for setting up IOA and putting IOA principles into action. Finally, this toolkit provides guidance on applying IOA in humanitarian and emergency contexts, offering a practical and adaptable approach to informing public health emergency responses.
Developed based on the model from the Democratic Republic of the Congo (DRC), its creation involved extensive consultation with experts experienced in IOA applications. The toolkit was piloted in Tanganyika Province, DRC, as well as Somalia and Sudan, demonstrating its adaptability to diverse emergency scenarios. It builds upon an existing array of tools, templates, reports, case studies, animations, and publications used by stakeholders in diverse contexts.
more
Access to safe, effective and quality-assured health products and technologies is crucial for achieving universal health coverage and primary health care goals. The continued growth of the aging population; increasing burden of noncommunicable diseases; growing burden of mental health issues; climat...e change; shifting patterns of vector borne diseases, fungal disease and waterborne diseases; antimicrobial resistance; and new infectious hazards create an ongoing need for equitable access to safe, effective and quality-assured health products and technologies, and renewed investments in research and development for innovative health products and technologies.
The coronavirus pandemic exposed the inequalities in access to health products, highlighting the need for longer-term strategies to strengthen access to health products and technologies outside of and in emergency situations. While technological and scientific advances present an opportunity to increase access to health products and technologies, the risk of increasing inequality due to higher prices for new health products and technologies; the persisting problem of substandard and falsified medical products; a lack of skilled workforce in many low- and middle-income countries; and a lack of data for decisionmaking and for measuring progress present significant challenges.
more
The 2024 edition reviews more than 50 health-related indicators from the Sustainable Development Goals and WHO’s Thirteenth General Programme of Work. It also highlights the findings from the Global health estimates 2021, notably the impact of the COVID-19 pandemic on life expectancy and healthy l...ife expectancy.
more
Despite being a preventable and curable infectious disease, tuberculosis (TB) has continued to elude global controll efforts. In 2023, 8.2 milion people with TB were diagnosed and notified to the WHO, the hightest number ever reported since WHO began tracking.
This publication provides an overview of evidence and guidance on the growing challenge of workplace heat stress in the context of climate change. It highlights the health and productivity risks faced by billions of workers, especially in manual labor sectors. The report details the physiological, s...ocioeconomic, and mental health impacts of heat stress and outlines evidence-based strategies for prevention and mitigation. It emphasizes the need for occupational heat action programmes, stakeholder collaboration, and tailored interventions to protect vulnerable workers, reduce productivity losses, and support sustainable development in a warming world.
more
On 27 September 2024, the Ministry of Health of Rwanda confirmed the country’s first outbreak of Marburg virus disease (MVD), with health-care workers in Kigali particularly affected. While sporadic outbreaks have occurred in various parts of Africa since the first recognized cases in 1967, this o...utbreak is the third largest outbreak of MVD ever recorded to date. Marburg virus disease is a severe disease clinically similar to Ebola disease. With no approved treatments or vaccines for MVD, early intervention for those showing symptoms is crucial for improving survival rates.
more
Conformément à son mandat, qui prévoit
qu’elle fournisse aux États Membres des orientations à caractère normatif en matière de
politique sanitaire, l’OMS publie une série de
notes de synthèse régulièrement mises à jour
sur les vaccins et les associations vaccinales
contre les ma...ladies ayant une incidence sur la
santé publique internationale. Ces notes de
synthèse portent essentiellement sur l’utilisation des vaccins dans le cadre de programmes
de vaccination à grande échelle.
more
L’orthopoxvirose simienne est une zoonose due à un virus du genre Orthopoxvirus de la famille des Poxviridés. La forme humaine de
la maladie a été identifiée pour la première fois en 1970 chez un garçon de neuf mois en République démocratique du Congo.
La République démocratique du Congo (RDC) mise sur la surveillance communautaire pour mieux riposter à la variole simienne appelée en anglais Mpox. En 2023, plus de 14 000 cas de Mpox ont été détectés. Le pays, avec l’appui de ses partenaires, forme les relais communautaires pour la sensib...ilisation de la population sur l’importance de se rendre rapidement à l’hôpital dès les premiers symptômes.
more
Uganda confirmed the first cases of mpox on 24 July 2024 following the confirmation of two case-patients from Kasese District, Bwera Hospital by the Uganda Virus Research Institute (UVRI) through a routine sentinel surveillance system. Cumulatively, 80 confirmed cases of mpox have been registered.
Du 09 janvier au 08 avril 2024, le Congo a confirmé 19 cas de Mpox dans 04 départements, à savoir : 14 cas dans la Cuvette, 02 cas dans la Likouala, 02 cas dans les Plateaux et 01 cas à Pointe-Noire. Au regard de cette situation, le Gouvernement de la République, via le Ministère de la Santé ...et de la Population, a déclaré, en date du 23 avril 2024, l’épidémie de Mpox conduisant à l’activation du COUSP1 en date du 03 mai 2024 avec la mise en place du Système de Gestion d’Incident (SGI) assorti de toutes ses fonctions essentielles et élargies sous l’approche « Une Seule Santé ». A la 39ème semaine épidémiologique, 1 nouveau cas a été confirmé par le LNSP2 dans le département de Brazzaville, DS de Madibou, dans l’aire de santé de Mansimou, donnant un total de 22 cas confirmés.
more
This course introduces Marburg Virus Disease and outlines the signs, symptoms, diagnosis, transmission routes and epidemiology of the disease. It also discusses prevention and control strategies.
In the Region of the Americas, as of 24 February 2023 (16:00 EST), there are a total of 58,578 confirmed cases of mpox (Table 1, Figure 2) were reported from 31 countries and territories, including 76 deaths in: United States of America (34), Brazil (15), Peru (15), Mexico (4), Chile (2), Ecuador (3...), Argentina (2), and Cuba (1), reported from 31 (Table 1, Annex 1, Figure 3). In the last 4 weeks (28 January – 24 February 2023), 607 additional mpox cases were reported from 16 countries and territories, including 9 deaths in Ecuador (1) and United States (8). Eight countries in the Region account for 97% of confirmed cases: United States of America, Brazil, Colombia, Mexico, Peru, Canada, Chile, and Argentina – listed by total number of cases in decrease order (Figure 4). The number of new weekly reported cases in EW 7 compared to EW 6 of 2023 (% variation) decreased by 55%.
more